Astellas, PeptiDream ink protein degrader pact

Today's Big News

Jul 25, 2023

Biogen is hungry for deals—but the less risk, the better


Roche drops solid tumor option, intensifying the squeeze on SQZ


Astellas notches another protein degrader pact with $21M upfront for PeptiDream


Stoke’s Dravet syndrome data spooks investors with high rates of adverse events


Humanigen mulls bankruptcy after reverse merger falls through


Heron lays off 25% of employees and renegotiates vendor contracts to save money


New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy


To prevent cancer metastasis, prevent protein migration, new study suggests


Fierce Biotech Fundraising Tracker '23: Crescendo raises $32M to fund Keytruda expansion arm; Renibus reels in $47M

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

Biogen is hungry for deals—but the less risk, the better

Biogen’s significant internal cost-cutting efforts have not deterred an aggressive hunt for deals, but CEO Chris Viehbacher doesn’t want infatuation to cloud necessary judgment. 
11-14
Sep
Philadelphia, PA
 

Top Stories

Roche drops solid tumor option, intensifying the squeeze on SQZ

The squeeze on SQZ Biotechnologies is getting tighter. After 12 months of value destruction, the biotech reported that Roche has dropped its option on a solid tumor program—and that it is assessing strategic alternatives to partner “all its clinical and preclinical assets across all disease areas and indications.”

Astellas notches another protein degrader pact with $21M upfront for PeptiDream

Is there anything Astellas likes more than a protein degrader pact? The Japanese pharma has followed up agreements with Cullgen and Generian Pharmaceuticals by tapping PeptiDream for its latest partnership.

Stoke’s Dravet syndrome data spooks investors with high rate of adverse events

One-third of patients experienced an adverse event related to Stoke Therapeutics’ Dravet syndrome treatment during a mid-stage clinical trial, sending shares down 30%.

Humanigen mulls bankruptcy after reverse merger falls through

Humanigen is running out of options. Talks over a reverse merger have collapsed and, with efforts to find another deal or raise funding failing, the biotech is considering filing for bankruptcy in the third quarter.

Heron lays off 25% of employees and renegotiates vendor contracts to save money

Heron Therapeutics is going through its second round of layoffs in 13 months, resulting in a 25% reduction of the team. The company is right-sizing its expenses due to rising costs in comparison to sales.

New mRNA vaccine for malaria uses cancer immunotherapy adjuvant to improve efficacy

Another mRNA vaccine for malaria is on the way. Its creators took a page from the cancer immunotherapy playbook to hopefully make it more effective.

To prevent cancer metastasis, prevent protein migration, new study suggests

Unexpected findings about how cell stress impacts gene expression have brought researchers a step closer to solving one of the many mysteries of cancer metastasis—and, potentially, to new ways to prevent it.

Fierce Biotech Fundraising Tracker '23: Crescendo raises $32M to fund Keytruda expansion arm; Renibus reels in $47M

Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Digital phenotyping, plus this week's headlines

This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines.

 

Resources

Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
Whitepaper

Improving the Patient Experience Through Research-Driven Design

Learn more about the current challenges and issues that eClinical technology providers are facing.

Research

Develop a cost-effective cGMP chemical sourcing strategy

The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Medical Affairs Metamorphosis

This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members.
eBook

6 Tools Trial Sponsors Need to Take Action Earlier in Enrollment

Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions.
Whitepaper

Enhance the cost-effectiveness of your GMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows.
 

Industry Events

 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events